Hello from PTN,
The conclusion of a year brings the unique opportunity to reflect on recent accomplishments, while also determining a path forward.
2020 has certainly been a year that has brought about unique circumstances, but PTN has risen to the occasion. I am immensely grateful for the flexibility, creativity, and dedication shown by the Network. Within this final 2020 newsletter, you will find highlights of some of our most recent achievements. I also hope you will check out our Annual Report, slated to be released in January, and read more about our successful year.
Thank you for all the contributions you make to making drugs safe and effective for all children.
I hope you have a wonderful holiday season.
|
|
|
Danny Benjamin, MD, PhD, MPH
Pediatric Trials Network, Principal Investigator
|
|
Coming in January...
The 2020
PTN Annual Report
|
|
Evaluating COVID-19 in Younger Patients
|
|
“With the increase in the number of COVID-19 cases, we are in dire need of more timely data on the use of therapeutics for children affected by COVID-19. The NICHD Funded POP02 Study is evaluating several therapeutics,” said Dr. Chi Hornik, POP02 Study Principal Investigator.
The drugs of interest currently being studied are: Anakinra, Aspirin, Azithromycin, Colchicine, Canakinumab, Interferon alpha & beta, Lopinavir/Ritonavir, Remdesivir, Ribavirin, Ruxolitinib, Sarilumab, and Tocilizumab.
|
|
|
Including Children with Down Syndrome in Clinical Trials
|
One of the three primary components of the INCLUDE initiative is to support clinical trials on conditions and diseases that affect people with Down syndrome, both to accelerate the development of new therapies for individuals with Down syndrome and to include them in ongoing clinical trials.
|
|
Recent PTN Publications
Jessica E Ericson, John McGuire, Marian G Michaels, Adam Schwarz, Robert Frenck, Jaime G Deville, Swati Agarwal, Adam M Bressler, Jamie Gao, Tracy Spears, Daniel K Benjamin Jr, P Brian Smith, John S Bradley, Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee and the Clinical Trials Transformation Initiative
Maybelle Kou, Aaron J Donoghue, Helen Stacks, Adam Kochman, Meghan Semião, Mark Nash, David Siegel, Lawrence Ku, Julie Debski, Jia-Yuh Chen, Gaurav Sharma, Leigh Gosnell, Steven Krug, Mark D Adler, Best Pharmaceuticals for Children Act – Pediatric Trials Network
Mihai Puia-Dumitrescu, Noelle Younge, Daniel K Benjamin, Katie Lawson, Cordelia Hume, Kennedy Hill, Jonathan Mengistu, Aryeona Wilson, Kanecia O Zimmerman, Kaashif Ahmad, Rachel G Greenberg
|
|
From NICHD
NICHD, part of the National Institutes of Health (NIH) and PTN's funder, leads research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all. Visit the NICHD our website to learn more.
The COVID-19 pandemic has been and continues to be foremost on researchers’ minds, both domestically and internationally. As distribution of vaccines begins in some areas, it’s important to note the NICHD’s and PTN’s vital contribution to understanding infection and treatment in children and teens:
-
Getting Radical about COVID-19. As part of the trans-NIH Rapid Acceleration of Diagnostics-Radical (RADx-Rad) initiative, NICHD and other institutes and centers are studying the Multisystem Inflammatory Syndrome in Children (MIS-C). This work will develop cutting-edge approaches for understanding the underlying factors influencing the spectrum of conditions, including MIS-C, that may occur in children and youth related to COVID-19. Learn more about the NICHD/PTN work on MIS-C.
-
Best Pharmaceuticals for Children Act (BPCA) continues to make a difference. BPCA research led to label changes on doxycycline, clindamycin, and caffeine citrate. Labels for these drugs now include information on recommended usage and dosage in pediatric populations. Learn more about these label changes.
|
|
Interested in
Participating in PTN Studies?
|
Currently enrolling:
Learn more about each study via the links below
Recruiting soon:
- Safety, Preliminary Effectiveness, and Pharmacokinetics (PK) of Drugs in Infants (Infant Master Protocol)
|
|
Process for Sharing Data and Samples
|
|
PTN is sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and provides pediatricians, researchers, and regulators with new information on how children respond to medications.
|
|
|
|
|
|
|